102988-93-2

Basic information

• Product Name: C₁₆H₂₁NO₆
• Synonyms: C₁₆H₂₁NO₆
• CAS NO: 102988-93-2
• Molecular Weight: 323.346
• Mol File: 102988-93-2.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: C₁₆H₂₁NO₆(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₆H₂₁NO₆(102988-93-2)
• EPA Substance Registry System: C₁₆H₂₁NO₆(102988-93-2)

Safety Data

• Hazardous Substances Data: 102988-93-2(Hazardous Substances Data)

Upstream product

• 26607-51-2 N-benzyloxycarbonyl-D-alanine 
• 543-27-1 isobutyl chloroformate 

Downstream Products

• 111633-10-4 {(R)-1-[Methyl-(3-phenyl-propyl)-carbamoyl]-ethyl}-carbamic acid benzyl ester 
• 148205-70-3 Z-D-Ala-Pro-Arg(NO₂)-Pro-OBzl 
• 148205-73-6 Z-D-Ala-Pro-Arg(NO₂)-Val-OBzl 
• 152169-60-3 benzyl {(2R)-1-[methoxy(methyl)amino]-1-oxopropan-2-yl}carbamate 
• 22209-85-4 (2S,2'R)-N-(N-Benzyloxycarbonylalanyl)proline methyl ester 
• 151378-81-3 benzyl [(1R)-2-amino-1-methyl-2-oxoethyl]carbamate 
• 176894-58-9 (2R)-2-(benzyloxycarbonylamino)propionitrile 
• 34276-31-8 benzyl N-[(1R)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]carbamate 
• 129474-02-8 Cbz-D-Ala-L-Pro-NH₂ 
• 105499-10-3 (R)-benzyl-(1-methyl-2-oxoethyl)carbamate 
• 177283-74-8 dibenzyl ((2R,3S,4S,5R)-3,4-dihydroxyhexane-2,5-diyl)dicarbamate 
• 177283-75-9 dibenzyl ((2R,3S,4S,5R)-3,4-bis((2-(trimethylsilyl)ethoxy)methoxy)hexane-2,5-diyl)dicarbamate 
• 68223-06-3 (3-diazo-1-(R)-methyl-2-oxopropyl)carbamic acid benzyl ester 

Relevant articles and documents

Synthesis and characterization of chiral di(N-protected-α-amino) diazo-β-diketones from α-diazoketones and imidazolides derived from amino acids

Di(N-protected-α-amino)diazo-β-diketones were prepared by the reaction of activated N-protected-α-amino acids (imidazolides) with α-diazoketones, derived from natural amino acids, in the presence of lithium diisopropylamide in tetrahydrofuran as the solvent at -78 °C.

Design and synthesis of cyclopenta[g]quinazoline-based antifolates as inhibitors of thymidylate synthase and potential antitumor agents

Following the development of raltitrexed, the synthesis of nonpolyglutamatable inhibitors of TS that do not use the reduced folate carrier (RFC) for cellular entry should provide compounds which overcome mechanisms of resistance to folate-based inhibitors

Preparation and structure-activity relationship of novel P1/P1'- substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors

A series of novel P1/P1'-substituted cyclic urea-based HIV-1 protease inhibitors was prepared. Three different synthetic schemes were used to assemble these compounds. The first approach uses amino acid-based starting materials and was originally used to prepare DMP 323. The other two approaches use L-tartaric acid or L-mannitol as the starting material. The required four contiguous R,S,S,R centers of the cyclic urea scaffold are introduced using substrate control methodology. Each approach has specific advantages based on the desired P1/P1' substituent. Designing analogs based on the enzyme's natural substrates provided compounds with reduced activity. Attempts at exploiting hydrogen bond sites in the S1/S1' pocket, suggested by molecular modeling studies, were not fruitful. Several analogs had better binding affinity compared to our initial leads. Modulating the compound's physical properties led to a 10-fold improvement in translation resulting in better overall antiviral activity.